Does the media refer more to JANX or TRDA?

In the previous week, Entrada Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 9 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.33 beat Entrada Therapeutics' score of 0.76 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRDA or SANA?

In the previous week, Sana Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 12 mentions for Sana Biotechnology and 11 mentions for Entrada Therapeutics. Sana Biotechnology's average media sentiment score of 0.85 beat Entrada Therapeutics' score of 0.76 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KURA or TRDA?

In the previous week, Kura Oncology had 13 more articles in the media than Entrada Therapeutics. MarketBeat recorded 24 mentions for Kura Oncology and 11 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.76 beat Kura Oncology's score of 0.74 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 10 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TRDA or CVAC?

Entrada Therapeutics presently has a consensus target price of $17.75, suggesting a potential upside of 153.57%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, TRDA or CVAC?

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entrada Therapeutics $25.42M 10.72 -$143.75M -$3.96 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Does the media prefer TRDA or AVTX?

In the previous week, Entrada Therapeutics had 9 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.94 beat Entrada Therapeutics' score of 0.76 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Entrada Therapeutics (TRDA) Competitors

$7.00 -0.27 (-3.71%)

As of 08/28/2026 04:00 PM Eastern

Compare

TRDA vs. JANX, SANA, KURA, CVAC, and AVTX

Should you buy Entrada Therapeutics stock or one of its competitors? Entrada Therapeutics's main competitors and comparable companies include Janux Therapeutics (JANX), Sana Biotechnology (SANA), Kura Oncology (KURA), CureVac (CVAC), and Avalo Therapeutics (AVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entrada Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Janux Therapeutics presently has a consensus target price of $36.46, indicating a potential upside of 102.23%. Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 153.57%. Given Entrada Therapeutics' higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Janux Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 9 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.33 beat Entrada Therapeutics' score of 0.76 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Janux Therapeutics' return on equity of -11.89% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Janux Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	110.24	-$113.62M	-$1.64	N/A
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Janux Therapeutics beats Entrada Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Entrada Therapeutics compare to Sana Biotechnology?

Entrada Therapeutics (NASDAQ:TRDA) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Sana Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 12 mentions for Sana Biotechnology and 11 mentions for Entrada Therapeutics. Sana Biotechnology's average media sentiment score of 0.85 beat Entrada Therapeutics' score of 0.76 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Sana Biotechnology	N/A	-103.02%	-39.16%

Entrada Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Entrada Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Entrada Therapeutics currently has a consensus target price of $17.75, indicating a potential upside of 153.57%. Sana Biotechnology has a consensus target price of $9.33, indicating a potential upside of 137.49%. Given Entrada Therapeutics' higher possible upside, research analysts plainly believe Entrada Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Sana Biotechnology beats Entrada Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Kura Oncology has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

In the previous week, Kura Oncology had 13 more articles in the media than Entrada Therapeutics. MarketBeat recorded 24 mentions for Kura Oncology and 11 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.76 beat Kura Oncology's score of 0.74 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	10 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	14.58	-$278.67M	-$3.37	N/A
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A

Kura Oncology has a net margin of -384.30% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Kura Oncology currently has a consensus target price of $25.40, indicating a potential upside of 100.63%. Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 153.57%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kura Oncology beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to CureVac?

Entrada Therapeutics (NASDAQ:TRDA) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

CureVac has a net margin of 199.92% compared to Entrada Therapeutics' net margin of -3,537.73%. CureVac's return on equity of -23.03% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
CureVac	199.92%	-23.03%	-19.09%

Entrada Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Entrada Therapeutics presently has a consensus target price of $17.75, suggesting a potential upside of 153.57%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Entrada Therapeutics had 11 more articles in the media than CureVac. MarketBeat recorded 11 mentions for Entrada Therapeutics and 0 mentions for CureVac. Entrada Therapeutics' average media sentiment score of 0.76 beat CureVac's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entrada Therapeutics	Positive
CureVac	Neutral

Summary

CureVac beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Avalo Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Entrada Therapeutics had 9 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.94 beat Entrada Therapeutics' score of 0.76 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A
Avalo Therapeutics	$60K	17,510.20	-$78.26M	-$4.37	N/A

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Avalo Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Entrada Therapeutics presently has a consensus price target of $17.75, indicating a potential upside of 153.57%. Avalo Therapeutics has a consensus price target of $45.10, indicating a potential upside of 130.22%. Given Entrada Therapeutics' higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Entrada Therapeutics and Avalo Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$272.56M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.77	11.62	273.16	25.45
Price / Sales	10.72	1,293.26	604.87	76.92
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	1.17	16.53	12.98	6.14
Net Income	-$143.75M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-7.53%	-0.31%	0.13%	-0.80%
1 Month Performance	3.40%	9.80%	7.08%	4.13%
1 Year Performance	27.97%	55.66%	24.67%	15.17%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	2.4755 of 5 stars	$7.00 -3.7%	$17.75 +153.6%	+28.0%	$272.56M	$25.42M	N/A	110	News Coverage Insider Trade Gap Up
JANX Janux Therapeutics	2.8717 of 5 stars	$18.68 +0.4%	$36.46 +95.2%	-20.6%	$1.14B	$10M	N/A	30	News Coverage Positive News
SANA Sana Biotechnology	2.417 of 5 stars	$4.10 +8.5%	$9.33 +127.6%	+28.4%	$1.13B	N/A	N/A	380	News Coverage Gap Up
KURA Kura Oncology	3.9205 of 5 stars	$13.59 +9.6%	$25.40 +86.9%	+60.3%	$1.10B	$67.48M	N/A	130	Gap Up High Trading Volume
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. JANX, SANA, KURA, CVAC, and AVTX

How does Entrada Therapeutics compare to Janux Therapeutics?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Summary

How does Entrada Therapeutics compare to CureVac?

Summary

How does Entrada Therapeutics compare to Avalo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. JANX, SANA, KURA, CVAC, and AVTX

How does Entrada Therapeutics compare to Janux Therapeutics?

Do analysts prefer JANX or TRDA?

Which has more volatility & risk, JANX or TRDA?

Does the media refer more to JANX or TRDA?

Is JANX or TRDA more profitable?

Which has stronger valuation & earnings, JANX or TRDA?

Do insiders & institutionals have more ownership in JANX or TRDA?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Does the media favor TRDA or SANA?

Is TRDA or SANA more profitable?

Which has more volatility & risk, TRDA or SANA?

Do institutionals and insiders believe in TRDA or SANA?

Which has higher earnings & valuation, TRDA or SANA?

Do analysts rate TRDA or SANA?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Which has more risk & volatility, KURA or TRDA?

Does the media favor KURA or TRDA?

Which has stronger earnings and valuation, KURA or TRDA?

Is KURA or TRDA more profitable?

Do analysts rate KURA or TRDA?

Do insiders & institutionals believe in KURA or TRDA?

Summary

How does Entrada Therapeutics compare to CureVac?

Is TRDA or CVAC more profitable?

Which has more volatility and risk, TRDA or CVAC?

Do analysts recommend TRDA or CVAC?

Do institutionals & insiders hold more shares of TRDA or CVAC?

Which has stronger earnings & valuation, TRDA or CVAC?

Does the media prefer TRDA or CVAC?

Summary

How does Entrada Therapeutics compare to Avalo Therapeutics?

Does the media prefer TRDA or AVTX?

Which has better earnings & valuation, TRDA or AVTX?

Do insiders & institutionals believe in TRDA or AVTX?

Is TRDA or AVTX more profitable?

Which has more volatility and risk, TRDA or AVTX?

Do analysts recommend TRDA or AVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools